濮阳东方妇科医院看病贵不贵(濮阳东方医院看男科好吗) (今日更新中)

The Washington Redskins are changing their name.According to the Sports Business Journal's John Ourand, the organization will announce the change on Monday. 164

The Trump administration is pushing back on a New York Times report that Education Secretary Betsy DeVos is looking into a plan that would allow states to use federal funding to buy firearms for teachers.On Wednesday, the Times reported that the Education Department was considering using a grant program called the Student Support and Academic Enrichment Program as a way to give federal funding for firearm purchases to states or school districts. The report cited multiple people with knowledge of the plan.A senior administration official told CNN that the idea laid out in the Times report did not originate with the Department of Education or DeVos. That official said the department received a letter from the Texas state Department of Education asking if the funds from a federal grant program could be used to purchase firearms. It was circulated to departmental lawyers and researchers for guidance, according to the official. The department ultimately chose not to respond, the official said.The official added that DeVos thinks that Congress should take action to clarify whether or not using the grant funding to buy guns is permissible. Moreover, the Education Department believes the grant program is intentionally vague to give school districts flexibility, and the idea of purchasing firearms was likely not considered when it was written, according to the official.In response to the Times report, Education Department spokeswoman Liz Hill told CNN that "the department is constantly considering and evaluating policy issues, particularly issues related to school safety. The secretary nor the department issues opinions on hypothetical scenarios."The discussion around arming teachers has been a deeply controversial one. President Donald Trump floated the proposal to arm educators and school staff on multiple occasions in the wake of the deadly school shooting at Marjory Stoneman Douglas High School in Parkland, Florida in February 2018."If you had a teacher who was adept with the firearm, they could end the attack very quickly," Trump said during a listening session on school safety a week after the shooting.The idea of arming school staff has been met with sharp condemnation.Former Congresswoman Gabrielle Giffords said in a statement Wednesday that "arming teachers is not a solution.""It recklessly puts American children in even more danger," she said in response to the Times report. "It's time for Americans to find the courage to take on the powerful and fight for our own safety."The American Federation of Teachers and the National Education Association also lambasted the proposal. Nicole Hockley, whose six-year-old son was killed in the 2012 Sandy Hook Elementary School shooting, took the microphone and told Trump she would rather arm teachers with ways to prevent shootings in the first place rather than with a firearm.Despite the criticism, Trump doubled down on the proposal on several subsequent occasions, and in March, the Trump administration proposed providing some school personnel with "rigorous" firearms training.In the wake of the Parkland shooting, the Trump administration also created a federal school safety commission, which is chaired by DeVos. In June, she testified before a congressional committee that the commission would not focus on looking at the role the role of guns in school safety. That stance was panned during a public forum. Democrats on the House Committee on Education and the Workforce have called on DeVos to explain how the commission will explore the role of guns."The Commission was charged with recommending policies and funding proposals to prevent school violence," 17 members of the committee wrote in a letter in June. "A core element of combating school violence is addressing gun violence, both in school and in our communities."The-CNN-Wire 3843

The search for a 12-year-old thought to be trapped in a Mexico City elementary school ended Thursday with the news that all students have been accounted for.But rescuers will continue their work, as signs suggest that someone may still be alive in the rubble, Angel Enrique Sarmiento, Mexico's sub-secretary of Navy, said Thursday.For days, Colegio Enrique Rebsamen was the site of a massive search and rescue operation offering a glimmer of hope in the chaotic aftermath of Tuesday's magnitude 7.1 quake. Reports of the missing 12-year-old riveted people across the country, who watched the rescue efforts unfold live on television. 656

The U.S. regulators who will decide the fate of COVID-19 vaccines are taking an unusual step: Asking outside scientists if their standards are high enough.The Food and Drug Administration may have to decide by year’s end whether to allow use of the first vaccines against the virus. Thursday, a federal advisory committee pulls back the curtain on that decision process, debating whether the guidelines FDA has set for vaccine developers are rigorous enough.“We will not cut corners, and we will only use science and data to make that determination,” FDA Commissioner Stephen Hahn pledged at a meeting of the Milken Institute Wednesday.Exactly how much data his agency needs to be sure a vaccine is safe and effective is a key question for the advisers. An even bigger one: If the FDA allows emergency use of a vaccine before final testing is finished, will that destroy chances of ever learning just how well that shot -- and maybe competitors still being studied -- really work?“We can’t lose sight of the fact that it is in our societal interest to see these trials to completion,” said Dr. Luciana Borio, a former FDA acting chief scientist who will be watching the advisers’ debate.Plus, multiple vaccines are being studied -- shots made with different technologies that each have pros and cons.“The first vaccine is not necessarily the best vaccine,” cautioned Dr. M. Miles Braun, a former FDA scientist now with Georgetown University School of Medicine. If the trials aren’t allowed to finish, it may be difficult or impossible to ever know for sure.It’s a critical moment in FDA’s 114-year history. The government has spent billions to race a vaccine through a research process that usually takes years, and FDA faces unprecedented pressure from the Trump administration, fueling public skepticism that politics could overrule science.Interest is so high, FDA is airing the meeting on YouTube. Here are some key issues the committee will discuss:HOW MUCH EVIDENCE IS NEEDED?FDA is requiring manufacturers to do studies of at least 30,000 people to prove if a vaccine protects and how safe it is. Those studies must include adequate numbers of people at highest risk from COVID-19 -- older adults, minorities and anyone with underlying health problems.FDA has made clear that any vaccine must be at least 50% effective. And while the studies are designed to run for two years, companies may get enough evidence the shots are protective -- in at least some people -- to stop the trials early and seek what’s called an “emergency use authorization” for wider vaccinations.Despite White House objections, the FDA told vaccine makers earlier this month not to seek that speedier review until they’ve tracked at least half their trial participants for two months. With other vaccines, that’s about the amount of time when major side effects crop up.That’s not long enough, said the head of the non-profit ECRI Institute, which reviews medical technology for hospitals and insurers. In comments submitted to the advisory committee, ECRI’s Dr. Marcus Schabacker said FDA should require six months of follow-up.“Doing any less would simply risk too much, and the consequences may be severe,” he wrote. “A weak vaccine that loses public trust could poison the well for epidemic control for many years.”WOULD EMERGENCY USE DERAIL FULL ANSWERS ABOUT VACCINES?Normally when a study ends because of evidence that a vaccine is working, the participants who got dummy shots are offered the real thing.But if FDA allows emergency use of a COVID-19 vaccine, that’s not the same as having full proof the shot works, Borio cautioned.And if the participants in the placebo group are immediately offered the real shot, researchers may not be able to get answers about all the high-risk groups in the study — or tell how long the vaccine’s protection lasts, a process expected to take many more months.But Pfizer Inc., which with Germany’s BioNTech is developing one of the leading candidates, told FDA that if it’s granted emergency use authorization, it “would have an ethical obligation” to alert study participants who got a placebo and allow them vaccine access. The company wants FDA to look into “other scientifically and statistically sound methods” to determine long-term safety and effectiveness.Pfizer’s stance is likely to face pushback. The Infectious Diseases Society of America states that FDA’s panelists “should insist” that vaccine developers “present a compelling case” for how they will complete their trials if FDA grants early authorization of their vaccine.Clearing a vaccine based on premature or faulty data “could cause more harm” by “further eroding public confidence in all vaccines,” the group said.It’s an unprecedented dilemma. The FDA has previously allowed emergency use of only one vaccine, a decades-old shot that in 2005 was authorized to prevent anthrax poisoning.This time around, multiple COVID-19 vaccines are in the pipeline. Pfizer competitor Johnson & Johnson cautioned that early FDA clearance of one vaccine could “jeopardize integrity” of other ongoing trials if patients decide to drop out to seek the first cleared shot instead.The company asked regulators to explain what options are available to ensure completion of all ongoing COVID-19 vaccine trials.WHAT ABOUT LONG-TERM SAFETY MONITORING?Even a study of 30,000 people cannot spot a side effect that only strikes 1 in 100,000. So the government is planning extra scrutiny of every COVID-19 vaccine to hit the market.At first there will be limited doses given to just certain high-risk people -- and those early recipients are to get text messages daily for the first week after vaccination, and then weekly out to six weeks, asking how they’re feeling.FDA also will be checking databases of electronic health records and insurance claims, looking for any red flags.“There’s a kind of tracking that has to take place here on a massive basis that hasn’t taken place before,” said Dr. Jesse Goodman of Georgetown University, a former director of the FDA’s vaccine and biologics center.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 6274

The Trump administration is taking steps to give telehealth a broader role under Medicare, with an executive order that serves as a call for Congress to make doctor visits via personal technology a permanent fixture of the program. The order President Donald Trump signed Monday applies to one segment of Medicare recipients — people living in rural communities. But administration officials say it’s intended as a signal to Congress that Trump is ready to sign more significant legislation that would permanently open up telehealth as an option for all people with Medicare. Trump says his administration is “taking action to make sure telehealth is here to stay.”"When the invisible enemy struck our shores, we took immediate action to eliminate regulatory barriers to telehealth, making it easier for patients to consult with doctors from safety and convenience and really, they have great safety and great convenience right from their homes," Trump said. While the CDC said in June it was working on expanding access to telehealth, it did list some drawbacks to the service:Situations in which in-person visits are more appropriate due to urgency, underlying health conditions, or inability to perform an adequate physical examThe need to address sensitive topics, especially if there is patient discomfort or concern for privacyLimited access to technological devices (e.g., smartphone, tablet, computer) needed for a telehealth visit or connectivity issuesLevel of comfort with technology for HCP and patientsCultural acceptance of conducting virtual visits in lieu of in-person visits by HCP and patientsInterstate licensure challenges and other regulatory issues that may vary by state 1701

来源：资阳报